{"component": "definition", "props": {"groups": [{"snippet": "means a human clinical study in any country conducted to evaluate the effectiveness of a drug for a particular indication or indications in patients with the disease or condition under study and, possibly, to determine the common short-term side effects and risks associated with the drug. In the United States, \u201cPhase 2 Clinical Study\u201d means a human clinical study that satisfies the requirements of 21 C.F.R. \u00a7 312.21 (b).", "size": 45, "samples": [{"hash": "gfUADU5KZqT", "uri": "/contracts/gfUADU5KZqT#phase-2-clinical-study", "label": "License Agreement (Parabilis Medicines, Inc.)", "score": 37.3778234086, "published": true}, {"hash": "8vCCX9CrI05", "uri": "/contracts/8vCCX9CrI05#phase-2-clinical-study", "label": "License Agreement (Parabilis Medicines, Inc.)", "score": 37.2491444216, "published": true}, {"hash": "2yQtp0vWQW5", "uri": "/contracts/2yQtp0vWQW5#phase-2-clinical-study", "label": "License Agreement (Evogene Ltd.)", "score": 37.2299804688, "published": true}], "snippet_links": [{"key": "determine-the", "type": "clause", "offset": [209, 222]}, {"key": "side-effects", "type": "clause", "offset": [241, 253]}, {"key": "associated-with", "type": "definition", "offset": [264, 279]}, {"key": "in-the-united-states", "type": "clause", "offset": [290, 310]}, {"key": "the-requirements", "type": "clause", "offset": [381, 397]}], "hash": "581dd668f929b810a70dfe6b8ba601e6", "id": 1}, {"snippet": "means controlled human clinical studies conducted to evaluate the effectiveness of a drug for a particular indication or indications in patients with the disease or condition under study and to determine the common short-term side effects and risks associated with the drug in compliance with 21 C.F.R. \u00a7312(b) or foreign equivalent, and shall include any clinical study that leads to a conditional regulatory approval, that is followed by a confirmatory Phase 3 Clinical Trial.", "size": 12, "samples": [{"hash": "7DCMb14AU4c", "uri": "/contracts/7DCMb14AU4c#phase-2-clinical-study", "label": "Patent License Agreement (Ziopharm Oncology Inc)", "score": 28.5989055634, "published": true}, {"hash": "2kdzLlLC8Wu", "uri": "/contracts/2kdzLlLC8Wu#phase-2-clinical-study", "label": "Patent License Agreement (Kite Pharma, Inc.)", "score": 26.2292957306, "published": true}, {"hash": "cAQaiGeUgDM", "uri": "/contracts/cAQaiGeUgDM#phase-2-clinical-study", "label": "First Amendment to L 068 2013/0 (Kite Pharma, Inc.)", "score": 24.1601638794, "published": true}], "snippet_links": [{"key": "clinical-studies", "type": "definition", "offset": [23, 39]}, {"key": "determine-the", "type": "clause", "offset": [194, 207]}, {"key": "side-effects", "type": "clause", "offset": [226, 238]}, {"key": "associated-with", "type": "definition", "offset": [249, 264]}, {"key": "in-compliance-with", "type": "definition", "offset": [274, 292]}, {"key": "foreign-equivalent", "type": "definition", "offset": [314, 332]}, {"key": "clinical-study", "type": "definition", "offset": [356, 370]}, {"key": "conditional-regulatory-approval", "type": "definition", "offset": [387, 418]}, {"key": "phase-3-clinical-trial", "type": "definition", "offset": [455, 477]}], "hash": "e240abeb4a96719f45ea26097ed050d7", "id": 2}, {"snippet": "means a human clinical study that satisfies the requirements of 21 C.F.R. \u00a7 312.21 (b).", "size": 11, "samples": [{"hash": "gfUADU5KZqT", "uri": "/contracts/gfUADU5KZqT#phase-2-clinical-study", "label": "License Agreement (Parabilis Medicines, Inc.)", "score": 37.3778234086, "published": true}, {"hash": "8vCCX9CrI05", "uri": "/contracts/8vCCX9CrI05#phase-2-clinical-study", "label": "License Agreement (Parabilis Medicines, Inc.)", "score": 37.2491444216, "published": true}, {"hash": "2yQtp0vWQW5", "uri": "/contracts/2yQtp0vWQW5#phase-2-clinical-study", "label": "License Agreement (Evogene Ltd.)", "score": 37.2299804688, "published": true}], "snippet_links": [{"key": "clinical-study", "type": "definition", "offset": [14, 28]}, {"key": "the-requirements", "type": "clause", "offset": [44, 60]}], "hash": "d2bb1645413147a7922ec24f835de4fa", "id": 3}, {"snippet": "means a clinical study of an investigational Product in human patients anywhere in the Territory conducted to evaluate the effectiveness of the Product for a particular indication or indications in patients with the disease or condition under study and to generate more detailed safety, tolerability, and pharmacokinetics information associated with the Product, as described in 21 C.F.R. \u00a7 312.21(b) (as amended or any replacement thereof), or a comparable clinical study required by the relevant Regulatory Authority in a country other than the United States.", "size": 6, "samples": [{"hash": "8AUl1CTgeeB", "uri": "/contracts/8AUl1CTgeeB#phase-2-clinical-study", "label": "Exclusive License Agreement (iBio, Inc.)", "score": 36.3045845032, "published": true}, {"hash": "i448A7VwdNv", "uri": "/contracts/i448A7VwdNv#phase-2-clinical-study", "label": "Exclusive License Agreement (iBio, Inc.)", "score": 36.0034217834, "published": true}, {"hash": "e5xkltk1BPh", "uri": "http://pdf.secdatabase.com/2730/0001420720-25-000020.pdf", "label": "pdf.secdatabase.com", "score": 20.2956829071, "published": false}], "snippet_links": [{"key": "clinical-study", "type": "definition", "offset": [8, 22]}, {"key": "investigational-product", "type": "definition", "offset": [29, 52]}, {"key": "in-the-territory", "type": "clause", "offset": [80, 96]}, {"key": "the-product", "type": "clause", "offset": [140, 151]}, {"key": "to-generate", "type": "definition", "offset": [253, 264]}, {"key": "associated-with", "type": "definition", "offset": [334, 349]}, {"key": "as-amended", "type": "definition", "offset": [402, 412]}, {"key": "required-by", "type": "definition", "offset": [473, 484]}, {"key": "relevant-regulatory-authority", "type": "definition", "offset": [489, 518]}, {"key": "the-united-states", "type": "definition", "offset": [543, 560]}], "hash": "8866bc1e2889f0ff6428b66154e71fe5", "id": 4}, {"snippet": "means a study of a Licensed Product in human patients that is intended to obtain information on the Licensed Product\u2019s activity for an indication at a prescribed (or otherwise limited) dose and administration schedule, as well as additional information on the Licensed Product\u2019s safety and toxicity as and to the extent defined for the United States in 21 C.F.R. \u00a7 312.21(b), or its successor regulation, or the equivalent regulation in any other country. Without limiting the generality of the foregoing, a clinical study shall be deemed to be a \u201cPhase 2 Clinical Study\u201d hereunder if such study has been designated by the sponsor as a Phase 2 [II] clinical trial on \u2587\u2587\u2587.\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587.\u2587\u2587\u2587 (or any successor website maintained by the U.S. National Institutes of Health (or any successor agency of the U.S. Government)).", "size": 5, "samples": [{"hash": "b1GlbQJi6gp", "uri": "/contracts/b1GlbQJi6gp#phase-2-clinical-study", "label": "License Agreement (CytomX Therapeutics, Inc.)", "score": 29.8459949493, "published": true}, {"hash": "Jckfm8G6w", "uri": "/contracts/Jckfm8G6w#phase-2-clinical-study", "label": "Research Collaboration Agreement (CytomX Therapeutics, Inc.)", "score": 26.7494869232, "published": true}, {"hash": "hTHrx0EV42k", "uri": "/contracts/hTHrx0EV42k#phase-2-clinical-study", "label": "Research Collaboration Agreement (CytomX Therapeutics, Inc.)", "score": 26.7385349274, "published": true}], "snippet_links": [{"key": "licensed-product", "type": "definition", "offset": [19, 35]}, {"key": "information-on", "type": "clause", "offset": [81, 95]}, {"key": "dose-and-administration", "type": "definition", "offset": [185, 208]}, {"key": "additional-information", "type": "definition", "offset": [230, 252]}, {"key": "safety-and", "type": "clause", "offset": [279, 289]}, {"key": "to-the-extent", "type": "clause", "offset": [306, 319]}, {"key": "for-the-united-states", "type": "clause", "offset": [328, 349]}, {"key": "without-limiting-the-generality-of-the-foregoing", "type": "clause", "offset": [456, 504]}, {"key": "the-sponsor", "type": "clause", "offset": [619, 630]}, {"key": "a-phase", "type": "definition", "offset": [634, 641]}, {"key": "clinical-trial", "type": "definition", "offset": [649, 663]}, {"key": "the-us", "type": "clause", "offset": [730, 737]}, {"key": "successor-agency", "type": "definition", "offset": [777, 793]}], "hash": "ee48c1c4274520e632e5954d4d9beaa6", "id": 5}, {"snippet": "means a clinical study in humans of the safety, dose ranging and efficacy of a pharmaceutical product, as further defined by Indian Regulatory Authorities, Federal Regulation 21 C.F.R. \u00a7 312.21(b) or its foreign equivalents.", "size": 5, "samples": [{"hash": "6nhML2vwLdm", "uri": "/contracts/6nhML2vwLdm#phase-2-clinical-study", "label": "License and Collaboration Agreement", "score": 36.243637085, "published": true}, {"hash": "fmgQo0m9L23", "uri": "/contracts/fmgQo0m9L23#phase-2-clinical-study", "label": "License and Collaboration Agreement", "score": 31.3408622742, "published": true}, {"hash": "iEbZyWb8RM3", "uri": "/contracts/iEbZyWb8RM3#phase-2-clinical-study", "label": "License and Collaboration Agreement (Visterra, Inc.)", "score": 27.0095825195, "published": true}], "snippet_links": [{"key": "clinical-study", "type": "definition", "offset": [8, 22]}, {"key": "the-safety", "type": "clause", "offset": [36, 46]}, {"key": "pharmaceutical-product", "type": "definition", "offset": [79, 101]}, {"key": "further-defined", "type": "clause", "offset": [106, 121]}, {"key": "regulatory-authorities", "type": "clause", "offset": [132, 154]}, {"key": "federal-regulation", "type": "clause", "offset": [156, 174]}], "hash": "8d2e9c91aa45f3d3d748afd49b06cdb1", "id": 6}, {"snippet": "means that portion of the drug development and review process which provides for early controlled clinical studies conducted to obtain preliminary data on the effectiveness of an investigational new drug for a particular indication that would satisfy the requirements specifically defined by the rules and regulations of the FDA under 21 \u00a7 C.F.R. 312.21(b), or similar rules and regulations in other countries or jurisdictions.", "size": 4, "samples": [{"hash": "1NX5PJqp5p7", "uri": "/contracts/1NX5PJqp5p7#phase-2-clinical-study", "label": "Exclusive Patent License Agreement (Signal Genetics, Inc.)", "score": 28.0088977814, "published": true}, {"hash": "1LJASSOXL5Z", "uri": "/contracts/1LJASSOXL5Z#phase-2-clinical-study", "label": "Exclusive Patent License Agreement (Signal Genetics, Inc.)", "score": 28.0088977814, "published": true}, {"hash": "8vObbjAFblo", "uri": "/contracts/8vObbjAFblo#phase-2-clinical-study", "label": "Exclusive Patent License Agreement (Signal Genetics, Inc.)", "score": 27.918548584, "published": true}], "snippet_links": [{"key": "drug-development", "type": "clause", "offset": [26, 42]}, {"key": "review-process", "type": "clause", "offset": [47, 61]}, {"key": "clinical-studies", "type": "definition", "offset": [98, 114]}, {"key": "preliminary-data", "type": "definition", "offset": [135, 151]}, {"key": "investigational-new-drug", "type": "definition", "offset": [179, 203]}, {"key": "the-requirements", "type": "clause", "offset": [251, 267]}, {"key": "specifically-defined", "type": "clause", "offset": [268, 288]}, {"key": "rules-and-regulations", "type": "clause", "offset": [296, 317]}, {"key": "the-fda", "type": "clause", "offset": [321, 328]}, {"key": "other-countries", "type": "definition", "offset": [394, 409]}], "hash": "c3016b2b67b538408fd8ef3ed9867441", "id": 7}, {"snippet": "means the second phase of a clinical study, the principal purpose of which is to evaluate the effectiveness of the drug for a particular indication and to determine the common short term side effects and risks associated with the drug in patients with the disease target being studied, that provides data capable of meeting statutory standards for marketing approval. Phase 2 studies usually involve no more than several hundred subjects. For example, \u201cPhase 2 Clinical Study\u201d includes a human clinical study that satisfies the requirements of 21 C.F.R. \u00a7 312.21(2) in the United States, or an equivalent or counterpart of the foregoing in any other country or jurisdiction.", "size": 3, "samples": [{"hash": "ixPjYSGsuGd", "uri": "/contracts/ixPjYSGsuGd#phase-2-clinical-study", "label": "Master Clinical Study Agreement", "score": 31.3408622742, "published": true}, {"hash": "fhsVDyK98ck", "uri": "/contracts/fhsVDyK98ck#phase-2-clinical-study", "label": "Master Clinical Study Agreement (Juno Therapeutics, Inc.)", "score": 25.9555091858, "published": true}, {"hash": "inqvQD2NENd", "uri": "/contracts/inqvQD2NENd#phase-2-clinical-study", "label": "Master Clinical Study Agreement (Juno Therapeutics, Inc.)", "score": 25.8761119843, "published": true}], "snippet_links": [{"key": "phase-of", "type": "clause", "offset": [17, 25]}, {"key": "purpose-of", "type": "clause", "offset": [58, 68]}, {"key": "effectiveness-of-the", "type": "clause", "offset": [94, 114]}, {"key": "determine-the", "type": "clause", "offset": [155, 168]}, {"key": "short-term", "type": "clause", "offset": [176, 186]}, {"key": "side-effects", "type": "clause", "offset": [187, 199]}, {"key": "associated-with", "type": "definition", "offset": [210, 225]}, {"key": "capable-of", "type": "definition", "offset": [305, 315]}, {"key": "marketing-approval", "type": "definition", "offset": [348, 366]}, {"key": "phase-2-studies", "type": "definition", "offset": [368, 383]}, {"key": "for-example", "type": "clause", "offset": [439, 450]}, {"key": "the-requirements", "type": "clause", "offset": [524, 540]}, {"key": "in-the-united-states", "type": "clause", "offset": [566, 586]}, {"key": "the-foregoing", "type": "definition", "offset": [623, 636]}], "hash": "214b3db8d4cfd52505bada508ab06924", "id": 8}, {"snippet": "has the same meaning as set forth in 21 C.F.R. Section 312.21(b), including any and all amendments, modifications or changes thereto as may be made thereto in the future, or the equivalent thereof, in any applicable country within the Territory.", "size": 3, "samples": [{"hash": "j5ehwuGvvYO", "uri": "/contracts/j5ehwuGvvYO#phase-2-clinical-study", "label": "License Agreement (Arena Pharmaceuticals Inc)", "score": 18.0, "published": true}, {"hash": "clxh5qpSAut", "uri": "/contracts/clxh5qpSAut#phase-2-clinical-study", "label": "Confidentiality Agreement (Arena Pharmaceuticals Inc)", "score": 18.0, "published": true}, {"hash": "77n4Z7ovErM", "uri": "/contracts/77n4Z7ovErM#phase-2-clinical-study", "label": "Confidentiality Agreement (Arena Pharmaceuticals Inc)", "score": 18.0, "published": true}], "snippet_links": [{"key": "same-meaning", "type": "clause", "offset": [8, 20]}, {"key": "modifications-or-changes", "type": "clause", "offset": [100, 124]}, {"key": "the-future", "type": "clause", "offset": [159, 169]}, {"key": "applicable-country", "type": "definition", "offset": [205, 223]}, {"key": "within-the-territory", "type": "definition", "offset": [224, 244]}], "hash": "9b168cfc1097009075e83a2a4de593ea", "id": 9}, {"snippet": "Phase 2 Clinical Study shall mean a study of a Compound in patients to determine additional safety information and initial efficacy and dose range finding.", "size": 3, "samples": [{"hash": "5karywOejrF", "uri": "/contracts/5karywOejrF#phase-2-clinical-study", "label": "Divestiture Agreement (Ophthotech Corp.)", "score": 24.6194381714, "published": true}, {"hash": "75g5NoUea1f", "uri": "/contracts/75g5NoUea1f#phase-2-clinical-study", "label": "Research and License Agreement (Archemix Corp.)", "score": 21.0, "published": true}, {"hash": "5ykWD9RkUgN", "uri": "/contracts/5ykWD9RkUgN#phase-2-clinical-study", "label": "Research and License Agreement (Nitromed Inc)", "score": 21.0, "published": true}], "snippet_links": [{"key": "to-determine", "type": "definition", "offset": [68, 80]}, {"key": "safety-information", "type": "definition", "offset": [92, 110]}], "hash": "907040d1649b5c2c77d3cbc0709cd93e", "id": 10}], "next_curs": "CmMSXWoVc35sYXdpbnNpZGVyY29udHJhY3Rzcj8LEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIfcGhhc2UtMi1jbGluaWNhbC1zdHVkeSMwMDAwMDAwYQyiAQJlbhgAIAA=", "definition": {"snippet": "means a human clinical study in any country conducted to evaluate the effectiveness of a drug for a particular indication or indications in patients with the disease or condition under study and, possibly, to determine the common short-term side effects and risks associated with the drug. In the United States, \u201cPhase 2 Clinical Study\u201d means a human clinical study that satisfies the requirements of 21 C.F.R. \u00a7 312.21 (b).", "size": 104, "title": "Phase 2 Clinical Study", "id": "phase-2-clinical-study", "examples": ["If a Clinical Study includes both a phase 1 portion and a phase 2 portion at the time of the Initiation of such Clinical Study, then the Initiation of the <strong>Phase 2 Clinical Study</strong> with respect to such Clinical Study shall be deemed to occur as of the date of the Initiation of the phase 2 portion of such Clinical Study."], "related": [["phase-i-clinical-study", "Phase I Clinical Study", "Phase I Clinical Study"], ["phase-2-clinical-trial", "Phase 2 Clinical Trial", "Phase 2 Clinical Trial"], ["phase-ii-clinical-study", "Phase II Clinical Study", "Phase II Clinical Study"], ["phase-1-clinical-trial", "Phase 1 Clinical Trial", "Phase 1 Clinical Trial"], ["phase-iii-clinical-study", "Phase III Clinical Study", "Phase III Clinical Study"]], "related_snippets": [], "updated": "2026-05-21T04:35:46+00:00"}, "json": true, "cursor": ""}}